Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo

Nature Medicine

Volumn 11, Issue 5, 2005, Pages 556-561

  Klyubin, Igor ^a   Walsh, Dominic M ^b,c   Lemere, Cynthia A ^b   Cullen, William K ^a   Shankar, Ganesh M ^b   Betts, Vicki ^c   Spooner, Edward T ^b   Jiang, Liying ^b   Anwyl, Roger ^a   Selkoe, Dennis J ^b   Rowan, Michael J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G8; MONOCLONAL ANTIBODY 6E10; MONOMER; OLIGOMER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; IMMUNOTHERAPY; LEARNING; LONG TERM POTENTIATION; MEMORY; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CHROMATOGRAPHY, GEL; CRICETINAE; CRICETULUS; ELECTROPHYSIOLOGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LONG-TERM POTENTIATION; NEURONAL PLASTICITY; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RATS; SYNAPSES;

ANIMALIA;

EID: 21044453723     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1234     Document Type: Article

References (30)

1. Nicoll, J.A.R. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, 448-452 (2003).
2. Hock, C. et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554 (2003).
3. McGeer, P.L. & McGeer, E. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol. Aging 24, 391-395 (2003).
4. Orgogozo, J.M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54 (2003).
5. Nicoll, J.A.R. et al. Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease - Reply. Nat. Med. 10, 118-119 (2004).
6. Schenk, D., Hagen, M. & Seubert, P. Current progress in β-amyloid immunotherapy. Curr. Opin. Immunol. 16, 599-606 (2004).
7. Robinson, S., Bishop, G., Lee, H. & Munch, G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging, 609-615 (2004).
8. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 915-919 (2000).
9. DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855 (2001).
10. Bacskai, B.J. et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369-372 (2001).
11. Dodart, J.C. et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457 (2002).
12. Kotilinek, L.A. et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335 (2002).
13. Wilcock, D.M. et al. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol. Dis. 15, 11-20 (2004).
14. Lue, L.F. et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862 (1999).
15. McLean, C.A. et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866 (1999).
16. Wang, J., Dickson, D.W., Trojanowski, J.Q. & Lee, V.M. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328-37 (1999).
17. Morris, R.G.M. et al. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358, 773-786 (2003).
18. Walsh, D.M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
19. Kim, K.S. et al. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci. Res. Commun. 2, 121-130 (1988).
20. Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B. & Selkoe, D.J. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831-10839 (2000).
21. Gong, Y.S. et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417-10422 (2003).
22. Wang, Q.W., Walsh, D.M., Rowan, M.J., Selkoe, D.J. & Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24, 3370-3378 (2004).
23. Chauhan, M., Siegel, G. & Lichtor, T. Distribution of intraventricularly administered antiamyloid-β peptide (Aβ) antibody in the mouse brain. J. Neurosci. Res. 66, 231-235 (2001).
24. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
25. Xia, W. et al. Presenilin 1 regulates the processing of β-amyloid precursor protein C-terminal fragments and the generation of amyloid β-protein in endoplasmic reticulum and Golgi. Biochemistry 37, 16465-16471 (1998).
26. Walsh, D.M. et al. Certain inhibitors of synthetic Aβ fibrillogenesis block oligomerization of natural Aβ and thereby rescue long term potentiation. J. Neurosci. 25, 2455-2462 (2005).
27. Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M. & Teplow, D.B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372 (1997).
28. Walsh, D. et al. Amyloid β-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952 (1999).
29. Lemere, C., Spooner, E., Leverone, J., Mori, C. & Clements, J. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol. Aging 23, 991-1000 (2002).
30. Lemere, C. et al. Sequence of deposition of heterogeneous amyloid-β peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32 (1996).